Skip to content

Omeros OMER Change in AP

Change in AP at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.67M-3.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$934K-115%
Immunome logo
ImmunomeIMNM
$1.42M+137%
Vor Biopharma logo
Vor BiopharmaVOR
-$9.1M-563%
Annexon logo
AnnexonANNX
$2.15M+7,039%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$3M-200%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's change in AP?
Omeros (OMER) reported change in AP of -$979K in Q1 2026.
How has Omeros's change in AP changed year-over-year?
Omeros's change in AP increased by 80.6% year-over-year, from -$5.04M to -$979K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.